OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted ...

OXFORD, United Kingdom, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced a research collaboration and option agreement with the ...

After a busy 2020, Evox Therapeutics is topping up its coffers to take its work to the next level. The U.K.-based biotech raised £69.2 million ($95.4 million) from the likes of OrbiMed and GV to ...

Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics OXFORD, United ...

Evox Therapeutics has raised £35.5 million ($45.4 million) to support its pipeline of exosome-based drugs. The series B, which attracted the support of GV, sets Evox up to take rare disease candidates ...

Series C financing will also be used for the development of Evox's DeliverEX exosome drug platform Oxford-based biotech company Evox Therapeutics has completed a Series C financing round, announcing ...

OXFORD, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted ...

Collaboration will focus on developing exosome therapeutics for rare diseases The University of Oxford’s Harrington Rare Disease Centre has entered a strategic collaboration agreement with Evox ...